Table 1:

Survival analysis of clinical features for all patients with ISCM (N = 49)

VariableMedian Survival (daysa) (95% CI)Hazard Ratio (95% CI)P Valueb
Age at diagnosis (yr) (N = 49)108 (48–156)1.02 (0.99–1.04).091
Primary malignancy.005
    Lung (n = 24)58 (31–120)–
    Breast (n = 7)48 (21–456)–
    Melanoma (n = 5)87 (15–734)–
    CNS (n = 4)763 (19–1261)–
    Renal (n = 3)299 (231–643)–
    Other (n = 6)503 (24–884)–
Lung/breast primary malignancy<.001
    Nonlung/nonbreast (n = 18)308 (87–689)–
    Lung/breast (n = 31)57 (33–117)–
Melanoma.635
    Nonmelanoma (n = 44)115 (40–166)–
    Melanoma (n = 5)87 (15–734)–
CNS primary malignancy.018
    Non-CNS (n = 45)104 (42–127)–
    CNS (n = 4)763 (19–1261)–
ISCM diagnosis precedes primary malignancy diagnosis.361
    No (n = 44)104 (42–184)–
    Yes (n = 5)127 (21–187)–

  • Note:— – indicates not applicable.

  • ↵a From the date of ISCM diagnosis.

  • ↵b P values are for log-rank tests for categoric variables and Wald tests for continuous variables.